Physician profile
Abraham Jacob
NPI 1679513626
$3,098.76
in general payments reported to CMS, 2019-2025
26 companies · $217 in 2025
The $217 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $122 · 2021: $658 · 2022: $428 · 2023: $350 · 2024: $674 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,241.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $519.55 | 2019-2024 | Ensite |
| Biotronik INC. | $408.07 | 2024-2025 | Biomonitor, Acticor 7 Vr-T Dx, Amvia Edge |
| Amgen INC. | $320.99 | 2019-2021 | |
| Boston Scientific Corporation | $278.35 | 2019-2025 | Latitude Communicator Power Supply, Watchman Access System |
| Sanofi-Aventis U.S. LLC | $252.50 | 2019-2022 | |
| Edwards Lifesciences Corporation | $143.85 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Merck Sharp & Dohme LLC | $126.97 | 2021-2023 | Verquvo |
| Shockwave Medical, INC | $119.04 | 2021 | |
| Philips North America LLC | $115.52 | 2024 | (9520) Igt Devices Undivided |
| Cvrx, INC. | $108.89 | 2022-2025 | Barostim Neo System |
| Itamar Medical INC | $107.09 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.90 | 2019 | |
| Pfizer INC. | $84.18 | 2022 | |
| Medicomp INC | $69.45 | 2021-2022 | |
| Medtronic, INC. | $61.24 | 2023-2025 | Onyx Frontier, Abre |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $46.19 | 2020-2021 | |
| Heartflow, INC. | $44.86 | 2023 | Ffrct |
| Novartis Pharmaceuticals Corporation | $41.33 | 2024 | |
| Alk-Abello, INC | $37.44 | 2024 | Odactra, Grastek, Ragwitek |
| Amarin Pharma, INC. | $30.03 | 2019-2021 | |
| Masimo Corporation | $22.00 | 2021 | |
| Medtronic Vascular, INC. | $18.07 | 2020 | |
| Esperion Therapeutics, INC. | $17.76 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.35 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.14 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.